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AbstrACt
Objective The reporting of outcomes in surgical trials 
for gastric cancer is inconsistent. The GASTROS study 
(GAstric Cancer surgery trials reported Outcome 
standardisation) aims to address this by developing a core 
outcome set (COS) for use in all future trials within this 
field. A COS should reflect the views of all stakeholders, 
including patients. We undertook a series of interviews to 
identify outcomes important to patients which would be 
considered for inclusion in a COS.
setting All interviews took place within the UK. Interviews 
were carried out face- to- face at hospitals and cancer 
support centres or via the telephone.
Participants Twenty participants at varying stages of 
recovery following surgery for gastric cancer with curative 
intent.
Design Qualitative design using semistructured 
interviews, supported by an interview guide which was 
iteratively modified; thematic analysis was used to explore 
patient priorities.
results Six themes enveloping 38 outcomes were 
identified; surviving and controlling cancer, technical 
aspects of surgery, adverse events from surgery, 
recovering from surgery, long- term problems following 
surgery and long- term life impact of surgery. The ‘most 
important’ patient priority was to be ‘cured of cancer’.
Conclusion Surgical trials for gastric cancer should 
consider broader priorities of patients when choosing 
which outcomes to report. This study highlighted the 
importance of longer- term outcomes such as cancer 
survival. Outcomes identified in this study will be used to 
inform an international Delphi survey to develop a COS in 
this field.
IntrODuCtIOn
background
Gastric cancer is a leading cause of cancer- 
related death worldwide.1 2 While surgery 
remains the only treatment which can offer 
a potential cure from this disease, it is associ-
ated with significant rates of morbidity in both 
the short and the long term.3 4 Ideally, the 
optimal surgical approach would minimise 
the risk of short- term and long- term compli-
cations without jeopardising the oncological 
resection.
Identifying the optimal surgical approach 
for gastric cancer should be based on 
comparing and combining robust clinical 
evidence from well- designed randomised 
controlled trials. One of the present chal-
lenges to achieving this is the inconsistency 
in the reporting of outcomes in this field.5 
This limits evidence synthesis and contrib-
utes to ‘research waste’. The GASTROS 
study (GASTROS—GAstric Cancer Surgery 
TRials Reported Outcome Standardisa-
tion—www. gastrosstudy. org)6 aims to address 
this issue by developing a ‘core outcome set’ 
(COS)—a minimum group of standardised 
strengths and limitations of this study
 ► This is the first in- depth qualitative study to examine 
the priorities and experiences of patients following 
potentially curative surgery for gastric cancer, and 
the first to establish which outcomes are important 
to patients.
 ► The study forms part of a larger project (The 
GASTROS Study—www.gastrosstudy.org) to devel-
op a ‘core outcome set’ for use in surgical trials for 
gastric cancer and was reviewed and funded by the 
National Institute of Health Research (UK). The study 
is based on a reproducible and transparent method-
ology which has been subjected to critical appraisal 
during a peer- review process.
 ► The term ‘outcome’ was described to participants in 
a manner relatable to them, such that they under-
stood it and were able to identify which outcomes 
were most important.
 ► The patient population was limited to UK- based 
English speakers. The views of international patients 
may vary due to differences in culture and clinical 
practice.
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and well- defined outcomes, measured by all future gastric 
cancer surgery trials.7
A guiding principle in the development of COS is 
that outcomes reflect the views and priorities of key 
stakeholders, including patients, to maximise the rele-
vance and impact of future research. Previous studies 
have demonstrated variations in the views and prior-
ities of clinicians and patients,8–10 which can result in 
trials reporting outcomes which bear little relevance to 
patients. A systematic review of outcome reporting in 
surgical trials for gastric cancer has demonstrated that 
outcomes which may be important to patients with gastric 
cancer, such as ‘quality of life’ after surgery, are poorly 
represented within this field.5 It is therefore important 
to understand which outcomes are important for patients 
undergoing gastric cancer surgery.
Objective
This research forms part of the GASTROS study, for 
which the protocol has been previously described.6 The 
first stage in the study involves identifying a ‘long- list’ 
of potentially important outcomes which will be priori-
tised in stage two by participants undertaking a Delphi 
survey. It is not known to what degree outcomes reported 
in previously published trials represent the priorities of 
patients undergoing gastric cancer surgery, and as such, 
solely relying on these as a source to populate the ‘long- 
list’ may overlook potentially important outcomes. By 
exploring the experiences, perceptions and priorities of 
patients who have undergone surgery for gastric cancer, 
this study aimed to identify outcomes which may not have 
been previously reported in the literature.
MethODs
study design
The role of qualitative research methods in the develop-
ment of COS has been previously explored11 and has been 
advocated by groups such as the Core Outcome Measures 
in Effectiveness Trials (COMET) initiative7 as one of 
several approaches to ensure that outcome lists being 
considered for prioritisation are exhaustive. This quali-
tative study used a semistructured interview approach to 
achieve the primary objective of identifying outcomes of 
importance to patients. A series of open questions were 
used to facilitate a patient- led discussion, guided by addi-
tional prompts from a pre- prepared interview schedule 
(table 1) to ensure key areas were covered.
Additional focused questioning around the use of 
outcomes in research was also included. In the context 
of clinical research, terms such as ‘outcomes’ may not be 
well understood by patients11 and so a mixture of open 
and closed questioning was important. Participant inter-
views were undertaken in series of three, following which 
transcript analysis (see below) was undertaken and the 
interview schedule was modified iteratively. This ensured 
that areas raised by earlier participants, but not included 
in the original schedule, were covered in subsequent 
discussions.
sampling
The eligibility criteria for this study are summarised in 
table 2. A purposive sampling strategy was adopted across 
the following characteristics:
 ► Age (above and below 70 years).
 ► Gender (men and women).
 ► Time since surgery (less than a year, 1–3 years and 
more than 3 years).
Interviews were undertaken until ‘data- saturation’ was 
achieved. Data saturation was determined when there 
was no new data emerging that had interpretive value.
(table 2)
Participants were recruited from across the UK from 
three sources:
1. A regional specialist gastric cancer centre: patients 
were approached in the outpatient clinic by their di-
rect care team.
2. Patient organisations: patient groups were asked to 
contact their membership through email and social 
media.
3. Snowball sampling; patients who had been recruited 
or contacted to participate were asked to identify other 
patients who would be interested in the study.
Data collection
Interviews were undertaken between February and May 
2017 and were conducted by BA, a consultant surgeon 
and researcher with approximately 10 years’ experi-
ence of managing and communicating with patients 
with gastric cancer. Participants were invited to choose 
between a University Teaching Hospital, two purpose- 
built patient cancer centres and their home for the loca-
tion of the meeting. Participants were also offered the 
opportunity to have their interviews over the telephone. 
Participants were offered travel expenses to minimise any 
financial burden on taking part in the study. In addition 
to the purposive sampling strategy, the following demo-
graphic data were collected:
 ► Gender (male/female).
 ► Social circumstances (eg, lives alone/with partner/
lives with dependents).
 ► Age.
 ► Time since surgery (in months).
 ► The type of gastrectomy (total or partial gastrectomy).
 ► The approach to their surgery (open or laparoscopic).
 ► Whether they had undergone additional treatment 
(eg, chemotherapy).
 ► Whether they had suffered a postoperative 
complication.
 ► Ethnicity.
 ► Previous trial enrolment.
 ► Participant’s postcode (to identify location and social 
deprivation score).
Full written consent was taken immediately prior to the 
interview and the participants were reminded that they 
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Table 1 Interview schedule
1. I understand you have (had) gastric cancer. Can you tell me about that?
2. Could you tell me about how you first found out you had gastric cancer?
Prompts:
 ► What questions did you most want to ask, when you were told that you had gastric cancer?
3 Were there were any areas you wanted more information about but were unable to find?
Prompts:
 ► Were you given any leaflets at the time of diagnosis? Did you find these useful?
4 What treatment was offered and how you decide about undergoing treatment.
Prompts:
 ► What information did you want about the treatment you would be receiving?
 ► What factors did you consider when deciding on the treatment?'
5 What effects did the treatment have on you after surgery?
Prompts:
 ► Did the treatment affect your physical or mental well- being?
 ► Did the treatment have an effect on relationships with those around you?
 ► Did you have to make any changes to your behaviour as a result of treatment?
6 What long- term effects did the treatment have on you?
Prompts:
 ► Did the treatment affect your physical or mental well- being?
 ► Did the treatment have an effect on relationships with those around you?
 ► Did you have to make any changes to your behaviour as a result of treatment?
7 What was the worst side effect of treatment?
8 What are your concerns for the future, especially those relating to their diagnosis/history of gastric cancer?
9 Did the explanation of what you should expect from surgery match your real experience?
10 In the context of research studies, can you explain what an outcome is in your own words?
The interviewer will then provide a definition of the term ‘outcome’ is in the context of clinical research.
11 What, in your opinion, is the most important outcome to measure in gastric cancer surgery trials?
12 Are there any other outcomes which may be important to measure?
13 Has your perspective on what is important changed over time?
14 Is there anything else that you feel is important to talk about that we have not discussed?
Table 2 Eligibility criteria for study participants
Potential participants approached Potential participants not approached
Participant  ► Male and female aged 18 years and older.
 ► Individuals able to participate in an interview in the 
English language.
 ► Patients unable to give informed consent
 ► Patients too unwell to comfortably participate in an 
interview lasting approximately 30–60 min.
Pathology  ► Adenocarcinoma and squamous cell carcinoma of 
the stomach (which makes up 95% of all stomach 
tumours).
 ► Gastrointestinal stromal tumours
 ► Neuroendocrine tumours
 ► Lymphoma
 ► Benign disease
Intervention  ► Total and partial gastrectomy
 ► Open and laparoscopic approaches
 ► Surgery with palliative intent
 ► Endoscopic therapies such as EMR (endoscopic 
mucosal resection) and ESD (endoscopic 
submucosal dissection)
can stop at any point or withdraw from the study without 
needing to give a reason.
Data analysis
All interviews were digitally recorded and profession-
ally transcribed (intelligent verbatim transcription). A 
thematic analysis was used to identify emerging themes 
and was guided by a general inductive approach.12 13 This 
was used to create the framework applied to subsequent 
interviews. Themes were developed using a three- step 
approach of open coding, axial coding and selective 
coding14 of the transcripts. Given the objective of this 
study was to identify themes and outcomes not previously 
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reported in trials, it was important not to base data 
analysis and outcome identification on a framework 
built on previously published literature. BA and RLM 
(a researcher with significant experience in qualitative 
research methods) independently analysed the first two 
transcripts and through discussion identified themes and 
adjustments to the interview schedule. There were no 
disagreements about coding, but had there been, these 
would have been discussed with the study management 
team. The final themes were agreed by all authors through 
discussion. Data analysis was supported using NVivo V.11 
(http://www. qsrinternational. com/ products_ nvivo. aspx, 
QSR International, Burlington, Massachusetts, USA).
Portfolio adoption
The study was adopted by the National Institute for 
Health Research (NIHR) Clinical Research Network Port-
folio (ID 33312).
reporting
This paper uses the SRQR checklist to structure the report 
of the study findings.15
Patient and public involvement
A Study Advisory Group (SAG) forms part of the manage-
ment structure of the wider GASTROS study,6 of which 
this qualitative study forms part of the first stage. The 
SAG is made up of key stakeholder representatives 
including patients, oncology nurses and surgeons. The 
group provides advice on the methodology of the study, 
general delivery of the study against its stated objectives 
and ensures that the viewpoints of all stakeholder groups 
are considered. The results of this study were presented 
to a SAG meeting; the ensuing discussion influenced the 
design of the next stage of the study in preparation for an 
an international Delphi survey.
Best practice guidelines for patient and public engage-
ment were followed as set out by INVOLVE (part of 
and funded by the UK’s National Institute for Health 
Research).16
results
Overview
In total, 20 patients were interviewed. Table 3 summarises 
demographic data and treatment- related characteristics 
of participants. Interviews lasted a median of 50.5 min 
(29–75 min). No patients withdrew from the study. 
Data saturation was deemed to have been reached by 
20 interviews; one new outcome was identified in inter-
view number 18 (related to sexual activity); however, no 
further outcomes were identified from the following two 
transcripts.
Outcome themes
Six broad themes enveloping 38 outcomes were identified:
1. Surviving and controlling cancer.
2. Technical aspects of surgery.
3. Adverse events from surgery.
4. Recovering from surgery.
5. Long- term problems following surgery.
6. Long- term life impact of surgery.
Online supplementary appendix 1 provides a break-
down of how all themes were developed from outcomes 
identified during the interviews. Themes were well 
represented in each interview; each theme was discussed 
by at least 18 of 20 participants. Online supplementary 
appendix 2 demonstrates the outcomes identified during 
the interviews and how often they were referenced.
Theme 1: surviving and controlling cancer
For most, details of their initial consultation were sketchy; 
participants often described being given lots of infor-
mation about their diagnosis, much of which was not 
absorbed. However, patients clearly remember their reac-
tion to being told their cancer diagnosis; for most, the 
response was the same:
When you hear the word, cancer, you think that’s it. 
I’m going to die. (Participant 6)
There was a range of personal experience with cancer 
within our patient group. Some had direct family 
members who had undergone chemotherapy and had an 
intimate knowledge of its effects.
It was my worst nightmare come true because I lost 
my dad to cancer and I always had it in the back 
of my mind, well if one person in the family could 
get cancer from somewhere then we could as well. 
(Participant 19)
Some patients had a vague knowledge of friends or work 
colleagues who had undergone treatments for cancer and 
others had no prior experience of cancer at all. Despite 
these differences, the initial responses to their diagnosis 
were similar.
All participants in our study had undergone radical 
surgery with curative intent. At the time of interview, no 
participants had confirmed evidence of disease recur-
rence, although one was being investigated for poten-
tial recurrence. Once the discussion with their surgeon 
moved away from the diagnosis and onto potentially cura-
tive treatments, participants often focused their questions 
on ‘survival’:
I wanted to know what the chances were of me having 
this removed and not, well, basically not dying from 
it. (Participant 4)
Despite radical surgery (and perioperative chemo-
therapy in half of our participants), for many of the 
participants the fear of recurrence remained a perma-
nent anxiety. Many participants seemed to understand 
that due to the aggressive nature of gastric cancer, recur-
rence is a possibility for many:
…you’re always worried that it’s going to come back… 
(Participant 7)
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The study cohort included participants who had under-
gone surgery between 5 months and 14 years prior to 
the interviews. There did not seem to be a relationship 
between the length of time out of surgery and concerns 
about cancer recurrence.
Theme 2: technical aspects of surgery
Several outcomes related to this theme were discussed by 
participants. Most importantly, participants focused on 
whether the surgical team was able to excise the ‘cancer’ 
in its entirety. This priority was often referenced in rela-
tion to the ‘success’ of surgery and its contribution to 
‘curing’ participants of cancer:
…thinking to yourself that, you know, everything has 
been done to the best of the hospital’s ability, and, 
you know, they’ve taken absolutely everything out. 
(Participant 4)
While participants mostly referred to the cancer as a 
single ‘entity’, there were a small number who demon-
strated some knowledge of the importance of different 
aspects of surgery such as lymph node excision:
And yeah, I remember the news about the pathology 
on the bits they’d taken away, and the lymph node 
system and what not, came a week or two before I was 
due to go back on the chemo. (Participant 20)
Six participants underwent a minimally invasive surgery 
with the remainder undergoing open surgery. The size of 
the wounds or type of surgical approach was referred to 
by only a minority of our participants. In the main, these 
were made in passing as little importance was placed on 
the surgical approach:
Interviewer: “Okay, and what…what did that mean 
for you to have keyhole surgery?”
Respondent: “It didn’t mean anything really, you 
know, I had…I’d heard about keyhole and people 
who’d had it.” (Participant 5)
Theme 3: adverse events following surgery
Eleven participants suffered a complication following 
surgery; however, this theme was important to all inter-
viewees. Perioperative death was the most frequently 
discussed surgical complication:
…the fear of dying on the operating table is really 
real. (Participant 2)
During their surgical consultation, participants 
retained some understanding of the risk of perioperative 
death and many were able to quote figures about how 
likely this complication was. Other complications were 
highlighted when recounting a personal experience. 
While all complications occurred in the postoperative 
period, there were several different causes attributed to 
these events (eg, direct surgical, anaesthesia- related and 
medication- related). The severity and consequences of 
the complications also varied significantly; some were 
self- limiting and resulted in a minor extension of the 
length of hospital stay:
But I was out of it for three days, I was just halluci-
nating and God knows what, probably because of the 
morphine. (Participant 7)
And those which were life- threatening and required 
significant clinical intervention:
It was a twisted bowel. Yeah, I was told it was a twist-
ed bowel. Because I always remember that when they 
brought me back from obviously having a look and 
everything, I always remember [they] said…we're go-
ing to have to take you back to surgery. (Participant 
15)
The severity of the complications suffered did not seem 
to shape the key priorities in relation to participants’ 
‘worst side effect’ of surgery or ‘most important outcome’; 
these almost entirely related to ‘long- term impacts of 
surgery’ and ‘cure’ respectively (see below) regardless 
of how long ago their operation was and which surgical 
approach (laparoscopic or open surgery) was employed.
While participants recounted that some of the more 
serious complications (eg, death, anastomotic leak and 
cardiopulmonary complications) were described by 
surgeons during the consent process, some were exposed 
to other sources of information in the preoperative stage. 
Participants were regularly provided with written infor-
mation about their cancer and its management; however 
the quality and content of this varied depending on the 
location of their hospital. The response to this format was 
varied:
I’m going to be honest with you, I didn’t actually 
read them… because I didn’t want things going in 
my head that I couldn’t take in. (Participant 17)
Participants that read the written information often 
found them difficult to digest for several reasons including 
the volume of information and fear of the gravity of the 
diagnosis or prognosis:
Well some of it were just waste of time, but others, 
you know, if you’ve got a book about that thick and 
you read through it and half of it applies to you, 
and the others just sort…doesn’t apply, you know. 
(Participant 5)
As much as it’s alright handing leaflets out, I can…I 
am a bit of a reader so I will read stuff, but when you 
think you’ve got a death sentence you think, what’s 
the point in reading that? (Participant 13)
Several hospitals had patient- support groups which 
provide a ‘buddy’ system for those awaiting surgery. 
These support groups became an important part of the 
recovery process and continue to be relevant many years 
after surgery. Patients found these more useful as they 
had the opportunity to speak to those with lived expe-
rience of the diagnosis and treatment. While this served 
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as an important source of information to tackle the 
longer- term impacts of surgery (below), these groups also 
provided comfort to patients:
I think the support group and speaking to people 
that have been through it, because it can demystify it 
quite a lot. (Participant 2)
Peer support also provided additional sources of infor-
mation to participants in the preoperative period with 
respect to some of the complications that could arise:
And I know one guy, where the oesophagus junction 
was, he’d had that leaking, and he couldn’t eat more 
than, like, grains of rice and things; so that would be 
pretty horrendous. (Participant 4)
As a result of verbal and written information from 
healthcare professionals and additional peer support, 
participants were able to describe key adverse without 
necessarily having experienced them firsthand.
Theme 4: recovery from surgery
Experiences during the immediate postoperative recovery 
period were referenced by 18 study participants. While 
some participants’ experience of recovery from surgery 
was directly linked to complications, there were aspects 
of recovery such as postoperative pain, mobility and the 
recommencement oral intake that were common among 
all those who spoke this theme.
Most participants did not mention postoperative pain 
as an important focus. Those that did, expected to suffer 
a degree of pain; however experiences of its severity 
varied widely. Pain levels among interviewees who had 
undergone similar operations through laparotomy inci-
sions were not uniform. One participant who had open 
surgery described:
I do remember waking up and really being in a hell of 
a lot of pain and being really out of it. (Participant 6)
While another who had undergone their surgery using 
the same approach recounted:
I didn't really have much pain. (Participant 14)
Discussions around postoperative pain were not 
confined to discomfort from the surgical incisions, but 
also related to postoperative complications:
I was back in writhing in agony with a serious infec-
tion in the wound. (Participant 9)
Participants recounted the limitations in their mobility 
during the postoperative period. There were many factors 
contributing to this, including physical weakness, not 
receiving appropriate encouragement to mobilise and 
being restricted by surgical drains:
…really difficult to be mobile I suppose, and move 
around, yourself, ‘cause obviously you’ve got quite a 
lot of tubes and different things coming out. I felt 
very, very swollen. (Participant 6)
Theme 5: long-term problems following surgery
All participants described significant long- term symp-
toms related to surgery. For the most, this represented 
the ‘worst side effect’ in relation to their treatment, and 
outcomes from this theme were referenced more than 
any other theme further emphasising its importance. All 
participants described experience with struggling to eat 
and drink following surgery and the majority (16/20) 
talked extensively about the impact of fatigue on their 
daily lives. Problems with maintaining weight, issues with 
ongoing gastrointestinal symptoms and chronic pain 
were discussed by most participants.
Fatigue was described in many ways; ‘exhaustion’, 
‘feeling tired all the time’, ‘feeling so weak’ and ‘having 
no energy’. For the main, fatigue was a symptom which 
persisted for months after surgery and could impact on 
a participant’s ability to undertake day- to- day activities or 
to socialise:
Well, I'm so weak, I used to go out, you know, and do 
fishing and do things with my lads. I'm just getting 
that little bit better now after 8 months, but I'm so 
weak and tired. (Participant 18)
Adapting to fatigue was and for many continued to be 
a difficult challenge; however many participants under-
stood that this was s a recognised and acceptable symptom 
to them given the magnitude of the surgery:
I've come out with…more…appreciation for look-
ing after myself and my…And if I'm tired, I stop. 
(Participant 15)
There were several causes for the struggles participants 
associated with eating and drinking. Participants often 
described having to eat and drink smaller volumes more 
frequently and some were unable to tolerate certain food 
types or consistencies. This had a direct effect on the 
pleasure associated with eating and an impact on where 
participants could eat:
Well I don’t eat what I would like to…But I know that 
for the rest of my life, I won't be able to go out for big 
meals, to big venues and eat like I used to eat before, 
you know. (Participant 5)
Most participants recounted being told prior to their 
surgery that their diet would be different and that they 
would have to ‘learn how to eat again’. Despite this, some 
participants felt that not enough information was given 
to highlight the true impact of this long- term issue and 
methods to address it:
I think it’s a lot worse than what they tell you. Because 
like some days, I'll eat a certain thing which I've ate 
before, and you just can't breathe properly, it's chok-
ing you. (Participant 18)
A broad range of gastrointestinal symptoms were 
reported by participants. The timeframe relating to how 
long these persisted was similarly broad (sometimes 
months and years) and did not seem to follow a pattern. 
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Nausea, vomiting, diarrhoea, reflux and belching were 
the the most common problems described. Many of these 
symptoms resulted in significant impacts on quality of life 
(see theme 6):
…I still get the bile reflux and I get this constant pain 
in the oesophagus which affects my sleeping as well. 
(Participant 7)
The dumping syndrome was mentioned. Never 
understood it until it happened. You know, how my 
body reacted to certain foods that I’d normally eat 
that it doesn't like anymore. (Participant 15)
Theme 6: long-term life impact of surgery
The long- term effects on ‘normality’, quality of life and 
psychological impact of surgery were discussed exten-
sively by all patients. A strong desire to return to a form of 
‘normality’ was regularly expressed. While the reference 
point for ‘normality’ differed among patients, common 
characteristics existed; namely, a desire to do what they 
used to do such as working, exercising, socialising with 
friends and family, and being able to travel:
It’s about living as I did before, and forgetting what 
had happened, and I do that quite often. (Participant 
6)
The experience of returning to normality varied among 
those interviewed. Many participants were largely able to 
return to their ‘normal’ activities although with some 
modifications:
Yes. I want to go on holidays again. I love cruises and 
I want…but until my eating’s improved, I wouldn’t do 
that. (Participant 1)
Now that it’s 18 months on, I am back to having what 
would be a normal life again, now, albeit with smaller 
portions of meals and things. (Participant 4)
Some participants, however, have not been able to 
return to activities that provided them with significant 
enjoyment:
I’ve never actually got back to my normal activity. I’ve 
never played golf since that day and I used to love 
golf. (Participant 4)
In general, participants understood that life after 
gastrectomy would be different:
I’m still alive, and then I need to get back to normal. 
It takes a while for you to realise your new normality 
is not like your old normality. (Participant 2)
While much of the discussion relating to ‘normality’ 
centred around specific tasks which participants valued 
or missed, the impact of gastrectomy on a participant’s 
overall general quality of life was important to many. Many 
understood that quality of life needed to be redefined in 
comparison to life before surgery, but nonetheless there 
was a minimum level that would need to be achieved:
If I have some sort of quality of life, where I can get 
up and wash myself and do, that is something that I’d 
live for. But I couldn’t be sat there and nursed 24/7. 
(Participant 17)
The psychological burden on participants following 
gastrectomy is a significant one. Each of the previously 
discussed themes could impact on a participant’s mental 
state, and while certain phases of the treatment pathway 
were time- limited, the psychological effects could persist 
for much longer;
You don’t just suffer from physical; you suffer from 
mental. And I think the mental is a lot more powerful 
that the physical, because you can shut pain off by 
taking medication, but it's very hard to shut problems 
off mentally. (Participant 18)
You know, ‘cause psychologically you think you’ve still 
got this poison in your body, as much as I’ve got rid 
of, you know, my monster. (Participant 13)
Some of the psychological impacts were associated with 
participants having to adapt to a new normality in rela-
tion to what they were able to do, what they were able to 
eat, how they looked physically or how they felt around 
others:
Well, it was a problem because like I say, I've always 
been a proud chap and proud of my body because I 
kept myself fit and everything. When I looked in the 
mirror, quite distressing. That was it, yeah. It makes 
you feel inferior. (Participant 18)
I feel a freak, I feel when I go into a big room with 
people that everybody has got a stomach and I haven’t 
got one, it’s not that I want them to know, but I just 
don’t feel the same anymore… (Participant 8)
Definition of ‘outcome’ by patients
All participants were asked what their understanding of 
the term ‘outcome’ was in the context of clinical research. 
Two participants were able to provide a broad- ranging 
definition which encompassed some of the benefits and 
adverse effects of treatment:
My perception of what would be meant by that phrase 
would…at a variety of levels; it could be does the pa-
tient live or die? Does the patient recover to an ac-
ceptable state for an extended period of time, and my 
understanding of what that might be, would be a, sort 
of, five year period… (Participant 20)
One person stated that they did not know how to define 
the term, while the remainder defined ‘outcome’ by 
recounting a single outcome, which was most important 
to them:
Okay, my understanding is that at the…the outcome 
would be that the cancer would be possibly all gone. 
(Participant 19)
by copyright.
 o
n
 February 27, 2020 at University of Bristol Library. Protected
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2019-034782 on 12 February 2020. Downloaded from 
9Alkhaffaf B, et al. BMJ Open 2020;10:e034782. doi:10.1136/bmjopen-2019-034782
Open access
Participants were asked to provide a single outcome 
that was ‘most important to them’. Fifteen participants 
identified that the most important outcome was that they 
were ‘cured of cancer’, with the remaining five describing 
outcomes related to ‘returning to normal’ and being able 
to enjoy a ‘good quality of life’. These priorities did not 
alter with respect to how long- ago surgery was performed, 
which approach was undertaken or how old the patient 
was.
DIsCussIOn
To our knowledge, this is the first in- depth qualitative 
study exploring the priorities of patients following poten-
tially curative surgery for gastric cancer. The study focused 
on this cohort as one of the main aims was to identify 
outcomes which would be considered for inclusion in 
a COS for potentially curative surgical trials in gastric 
cancer. This present study will be used to help generate 
a list of outcomes that will be presented for prioritisation 
to healthcare professionals and patients in an interna-
tional, multilanguage online Delphi survey. The results 
of the Delphi survey will inform a consensus meeting to 
finalise the COS. While other COS studies in the field 
of cancer17–19 may have identified similar important 
outcomes such as survival, it was important to consider our 
participants separately given the unique problems which 
arise with gastrectomy. These include distinctive short- 
term and long- term problems related to surgery such as 
anastomotic leak and reactive hypoglycaemia (dumping 
syndrome) which would not be relevant in other COS.
The themes identified highlight the profound and 
wide- ranging physical, social and psychological impacts 
that gastrectomy has on patients which can persist for 
months and years. We have previously described the 
reporting of outcomes in surgical trials for gastric cancer 
over a 20- year period.5 Most surgical trials in this field have 
focused on reporting short- term postoperative outcomes. 
While these are important to patients, they are not repre-
sentative of the whole picture. This work highlights how 
patient priorities for outcomes may differ from the tradi-
tional surgical focus. More work is now needed to develop 
the COS which incorporates views of all key stakeholders 
including patients.
More than half of the ‘top- ten’ most frequently discussed 
outcomes in our study related to longer- term issues 
such as problems with eating, returning to ‘normality’, 
fatigue, weight loss, gastrointestinal symptoms and 
psychological impacts. These types of outcomes are infre-
quently reported in surgical trials and demonstrate that 
researchers within this field have not reflected the prior-
ities of patients. This challenge needs to be addressed 
using an approach which is inclusive of patients and their 
views.
The GASTROS study aims to develop a COS; critically 
important outcomes which should be reported—as a 
minimum—by future surgical trials for gastric cancer.6 
By standardising the reporting of such outcomes, it aims 
to improve the ability to synthesise evidence, reduce 
research waste and ultimately aid researchers in answering 
important questions related to gastrectomy. The first 
stage in developing the COS consists of identifying a 
‘long- list’ of outcomes which will then be prioritised by 
key stakeholders during an international online Delphi 
survey. The process of developing the long- list should be 
comprehensive and involve both healthcare professionals 
and patients in order to minimise the risk of omitting 
potentially important outcomes. Our study reaffirms the 
importance of a mixed- methods approach to identifying 
potentially important outcomes. As other COS developers 
have found, building a long- list based solely on outcomes 
reported in previous trials or as developed by clinicians 
often neglects the views of key stakeholders.8–10 This 
ultimately runs the risk of producing a COS which does 
not reflect the priorities of patients which does little to 
address the current challenges with outcome reporting.
Understanding patient priorities following gastrectomy 
is invaluable for other reasons. Patients with gastric cancer 
want detailed information about their condition and 
treatment.20 With the knowledge that long- term impacts 
of surgery are important, healthcare professionals can 
tailor the consent process prior to surgery to ensure that 
the patient has a better understanding of these and is 
making an informed decision. Considering patient prior-
ities may also have implications for the future develop-
ment of national and international audits.3 4 For several 
pragmatic reasons, most comprehensive gastric cancer 
surgery audits focus on short- term outcomes. Identifying 
methods to report longer- term quality outcome measures 
may make such audits more relevant to patients. Studies 
assessing patients’ views in similar disease areas found 
similar things, that long- term outcomes (survival and 
long term quality of life) were important.21
strengths and weaknesses
The study was able to gain an in- depth understanding 
of patient priorities based on the experience of partic-
ipants with a broad range of characteristics representa-
tive of those undergoing surgery for gastric cancer in the 
UK.4 Furthermore, our purposive sampling approach was 
established a priori in a study protocol which had under-
gone a robust peer- review process.
This study was also able to highlight and address signif-
icant challenges associated with the comprehension of 
medical language by patients; particularly terms central 
to the development of a COS. Patients largely did not 
understand the use of the term ‘outcome’ within the 
context of medical research. Once it was defined as an 
‘impact or effect of a treatment which may be beneficial 
or harmful’, participants were more easily able to describe 
their key priorities in outcome reporting for future trials. 
This has several implications for the GASTROS study as 
well as other COS projects moving forward. It highlights 
the importance of ensuring that the premise of the study 
is clear and understood by all participants, especially 
patients; outcomes included in the Delphi survey must be 
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presented and explained in a manner which is accessible 
to all; ‘outcome’ must be clear when adapting it to other 
regions where there may be no direct translation for the 
term.
The interviews were conducted by an expert in the 
field of gastric cancer surgery which may have resulted 
in a degree of observer bias. To mitigate this potential 
limitation, the study management team (which was made 
up primarily of members unfamiliar with gastric cancer 
surgery) was involved in ongoing discussions during data 
collection and analysis. It is also possible that patients 
modified their responses because of awareness of the 
background of the interviewer. Every effort was made to 
follow the semistructured interview schedule, to put the 
patients at ease and take time to let them talk. The average 
length of the interviews (greater than 45 min) reflects the 
time patients were given to express their views.
A further potential limitation of this present inter-
view study is a lack of international patient participation. 
Consequently, there may be outcomes which are relevant 
to non- UK patients that have not been identified. Gastric 
cancer is an international disease, and cultural and 
regional influences may alter expectations and priorities 
of patients. While we have not identified evidence from 
COS developers in other fields that confirms these vari-
ations, it remains a possibility. Our reasons for limiting 
the interviews to UK- only patients were primarily down 
to pragmatism and finite resources. To mitigate this, 
the Delphi survey will be available in several languages 
and during the first round, all participants will be able 
to submit additional outcomes that they believe were 
omitted. These will be considered by the study team 
and presented for prioritisation by participants in round 
two of the Delphi survey, if appropriate. Adopting this 
approach also enables the exploration of regional varia-
tions in outcome priorities which may form the basis of a 
future international qualitative study.
This study focuses primarily on the impact of gastrec-
tomy from the perspective of patients. However, we 
acknowledge that major complex surgery such as gastrec-
tomy inevitably results in both direct and indirect effects 
on family members and caregivers. While these wider 
impacts warrant further examination, we limited partic-
ipation in this present study to patients, as the scope of 
the COS aims to consider the perspective and priorities 
of patients, surgeons and oncology nurses. Part of our 
planned future work is to review the COS to ensure that 
it remains up- to- date and relevant. At this point, it will 
be possible to widen participation beyond these three 
groups to include caregivers and other allied healthcare 
professionals.
Recruitment to the study stopped when no new data 
with interpretative value were identified.22 However, 
‘data saturation’ is a topic which deserves further discus-
sion as there is no way of knowing for certain that no 
new outcomes would have been identified had further 
interviews been undertaken. Some argue that the term 
‘data saturation’ is often misused and misunderstood 
and should be operationalised in a way consistent with 
the scope of the study being undertaken.23 As described 
above, the ability of patients and healthcare participants 
to suggest further outcomes in round one of the Delphi 
survey aims to mitigate against this potential limitation.
Most participants had undergone their surgery at 
least 12 months prior to this study. As such, it should be 
acknowledged that there may have been a greater explo-
ration of and emphasis on shorter- term outcomes had we 
recruited more participants from a shorter postoperative 
time period. Again, to address this potential limitation, 
we plan to recruit participants for the Delphi survey from 
all postoperative periods and will have the opportunity 
to examine whether ‘time from surgery’ affects patient 
priorities.
In summary, this study identified 38 unique outcomes 
which are important to patients following surgery for 
gastric cancer. Many of these outcomes are poorly repre-
sented by trials within this research field. These outcomes 
will be added to other potentially important outcomes 
to be considered for prioritisation by key stakeholders to 
develop a COS for surgical trials in gastric cancer.
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